Easton Pharmaceuticals Strengthens its Board of Directors While Enhancing Existing Businesses and Moves Towards New Sectors and Industries
TORONTO, ON, June 25, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals Inc. (OTC:EAPH) is pleased to announce the appointment of Mr. Panagis (“Panos”) Alivizatos, to its Board of Directors to enhance existing businesses and moves towards new sectors and industries.
Mr. Alivizatos has over 17 years of working experience in the Investment Banking and Corporate Finance sector spanning from M&As, capital markets to project finance, structured finance and P3. He has worked for top tier investment banks, such as Credit Agricole CIB, as well as in international corporate finance boutiques and multinational corporations in Director level positions in the functions of corporate development, investments and strategic planning. He has advised Middle East based governmental organizations in project development (PPP) related to real estate and housing. He has lived and worked in Europe, Middle East and Africa. He has vast transactional experience throughout a variety of funding structures, combined with significant hands-on operational know-how and experience gained in the sectors of Financial Services, Renewable Energy, Real Estate, TMT, Natural Resources, Infra, Transportation and Life Sciences. He has overseen a number of different transactions including M&As, Valuations, Joint Ventures, Partnerships, Fund-Raisings (ECM/DCM), Divestitures, De-listings and IPOs.
Mr. Alivizatos is a London Business School alum (holding a certificate in Corporate Finance) and he holds a master’s degree in Finance (University of Leicester, UK), a bachelor’s degree in Business Administration and Management (Piraeus University of Applied Sciences, Greece) and a certificate in Law & Economics (Law School of Athens, Greece).
“We are pleased to welcome Mr. Alivizatos to our Board,” stated Mr. Evan Karras, President & CEO of Easton Pharmaceuticals Inc. Mr. Karras further stated, “I’m excited to welcome a former colleague and a good friend to our Board. I believe Panos’ international experience in business, his contacts and his expertise in investment banking and corporate finance will be extremely beneficial for us as we look to advance our pipeline of businesses, transactions and restructure our company to include more lucrative opportunities.”
Easton Pharmaceuticals is planning to announce additional changes, including a name change to better reflect its diversifying business segments, as the company gears up to enter additional lucrative business segments and industries, by investing in Real Estate, Gaming, Aggregates, Life Sciences (including Recreational / Medical Marijuana), Natural Resources and TMT (including AI, fintech, blockchain and mobile technologies).
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other industries, which includes soil, aggregate, recycling, pharmaceuticals, diagnostic and other growing industries including medical / recreational marijuana. The Company previously developed and owned an FDA-approved wound healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica S.A. and together own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis. In addition, a generic cancer drug line is currently in the approval process for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system.
For More Information On Easton and Affiliated and Partner Companies Visit:
http://www.eastonpharmaceuticalsinc.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
CONTACT: Contact: Investor Relations Tel: +1(416) 619-0291 Tel: +1(347) 284-0192 Email: info@eastonpharmaceuticalsinc.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Tesla (Nasdaq: TSLA) Announces Date for First Quarter 2021 Financial Results and Webcast
